NV
Novo Nordisk
NVO · NYSE
$46.63 -1.86% (-$0.89)
1M -1.40%
Market Cap 1.36T kr
P/E Ratio 11.65x
Div. Yield 3.78%
ROE 59.09%
Bulios Fair Price
$61.4
31.7% upside
Trenutna cena
$46.63
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica NVO trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Moderate
6/9Valuation
61 /100
Fair P/E 11.65x
EV/EBITDA 8.03x
PEG 9.25x
Growth
75 /100
Growing EPS growth 23.52%
Rev. growth 20.43%
Book val. growth 32.46%
Profitability
96 /100
Strong Gross margin 80.65%
Net margin 35.35%
FCF margin 14.85%
Quality
92 /100
Excellent ROIC 29.73%
ROE 59.09%
Asset turnover 0.55x
Debt
81 /100
Low Debt/Equity 0.63x
Current ratio 0.87x
Net debt/EBITDA 0.53x
Stability
70 /100
Stable Beta 0.35x
Rev. volatility 12.92%
Profitable years 6
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o NVO
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Maziar Mike Doustdar
Employees
68,794
Headquarters
Bagsvaerd
Prihajajoči dogodki
04 NOV.
Earnings
Upcoming earnings report